(CercleFinance.com) – GSK announced on Thursday that Arexvy, its respiratory syncytial virus vaccine for the elderly, is now available in pharmacies in the United States.
The launch comes as the US FDA last June approved the vaccine, intended to prevent lower respiratory tract disease caused by RSV in adults over the age of 60.
GSK says that under the Inflation Reduction Act, patients eligible for Medicare’s Part D plan will not have to pay any upfront costs if they choose to be vaccinated.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
This is a Smartvoice article: see legal notice